HRP970715A2 - Sustained release cisapride mini-tablet formulation - Google Patents

Sustained release cisapride mini-tablet formulation

Info

Publication number
HRP970715A2
HRP970715A2 HR60/035,027A HRP970715A HRP970715A2 HR P970715 A2 HRP970715 A2 HR P970715A2 HR P970715 A HRP970715 A HR P970715A HR P970715 A2 HRP970715 A2 HR P970715A2
Authority
HR
Croatia
Prior art keywords
mini
sustained release
tablet formulation
release cisapride
cisapride
Prior art date
Application number
HR60/035,027A
Other languages
English (en)
Inventor
Kenneth Iain Cumming
Original Assignee
Kenneth Iain Cumming
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE970001A external-priority patent/IE970001A1/en
Application filed by Kenneth Iain Cumming filed Critical Kenneth Iain Cumming
Publication of HRP970715A2 publication Critical patent/HRP970715A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR60/035,027A 1997-01-03 1997-12-30 Sustained release cisapride mini-tablet formulation HRP970715A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE970001A IE970001A1 (en) 1997-01-03 1997-01-03 Sustained release cisapride mini-tablet formulation
US3502797P 1997-01-13 1997-01-13

Publications (1)

Publication Number Publication Date
HRP970715A2 true HRP970715A2 (en) 1998-10-31

Family

ID=26319999

Family Applications (1)

Application Number Title Priority Date Filing Date
HR60/035,027A HRP970715A2 (en) 1997-01-03 1997-12-30 Sustained release cisapride mini-tablet formulation

Country Status (7)

Country Link
US (1) US6110494A (de)
EP (1) EP0951278A2 (de)
JP (1) JP2001507359A (de)
AU (1) AU7888298A (de)
CA (1) CA2275604A1 (de)
HR (1) HRP970715A2 (de)
WO (1) WO1998029095A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
TW407058B (en) 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
WO2000069420A1 (en) * 1999-05-14 2000-11-23 Coraltis Ltd. Pulse-delivery oral compositions
EP1060743A1 (de) * 1999-06-17 2000-12-20 Development Center For Biotechnology Orale Dosierungsformen von Cisapride mit verlängerter Wirkdauer
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
PT1443917E (pt) * 2001-11-07 2006-06-30 Synthon Bv Comprimidos de tamsulosina
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
JP4493970B2 (ja) * 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP1552833B1 (de) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Herstellung eines amorphen, optisch aktiven Isomers von Lansoprazol
WO2005051322A2 (en) 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
ZA200606409B (en) * 2004-01-06 2008-06-25 Panacea Biotec Ltd Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
EP1768668A2 (de) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multi-ppi-dosierform
MX2007002594A (es) * 2004-09-02 2007-04-25 Janssen Pharmaceutica Nv Fumarato de 4-((4-((4- (2-cianoetenil)-2, 6-dimetilfenil) amino)-2-pirimidinil) amino) benzonitrilo.
US20060078621A1 (en) * 2004-10-13 2006-04-13 Wedinger Robert S Method of providing customized drug delivery systems
MX2007008833A (es) * 2005-01-21 2008-03-25 Pharmanova Inc Formulaciones farmaceuticas y metodos de uso.
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
CN102014638A (zh) 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
KR101190708B1 (ko) * 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
CN105640954B (zh) * 2016-02-04 2019-03-05 青岛市海慈医疗集团 一种治疗消化不良的西沙必利片剂
JP7426685B2 (ja) * 2018-06-14 2024-02-02 株式会社東洋新薬 錠剤

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205073A (en) * 1975-04-30 1980-05-27 Schering Corporation Anti-diarrheal anilino nicotinic acids and method of using same
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IT1176853B (it) * 1984-10-02 1987-08-18 Eurand Spa Procedimento per ottenere una formulazione a rilascio controllato di componenti solubili in acqua
US4609909A (en) * 1985-03-04 1986-09-02 Gte Government Systems Corporation Multimode perimeter intrusion detection system
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US5238686A (en) * 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5624683A (en) * 1986-08-06 1997-04-29 Eisai Co., Ltd. Sustained-release multi-granule tablet
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
EP0325086A3 (de) * 1987-11-23 1990-10-31 Jago Research Ag Verfahren zur Herstellung von therapeutischen Systemen mit gesteuerter Freigabe des Wirkstoffes
GB8801863D0 (en) * 1988-01-28 1988-02-24 Fulmer Yarsley Ltd Pharmaceutical formulations with controlled drug release
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
DE4004430A1 (de) * 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
EP0548553A1 (de) * 1991-11-25 1993-06-30 Takeda Chemical Industries, Ltd. Optisch aktive Azolverbindungen, ihre Herstellung und Anwendung
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
WO1994005262A1 (en) * 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
MY113429A (en) * 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US6126970A (en) * 1995-12-01 2000-10-03 Janssen Pharmaceutica N.V. Cisapride sustained release
EP0803251B1 (de) * 1996-04-23 2002-07-17 Janssen Pharmaceutica N.V. Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid

Also Published As

Publication number Publication date
AU7888298A (en) 1998-07-31
JP2001507359A (ja) 2001-06-05
WO1998029095A2 (en) 1998-07-09
WO1998029095A3 (en) 1998-09-11
CA2275604A1 (en) 1998-07-09
US6110494A (en) 2000-08-29
EP0951278A2 (de) 1999-10-27

Similar Documents

Publication Publication Date Title
EG24198A (en) Extended release formulation
GB9826662D0 (en) Controlled release formulation
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
SG71879A1 (en) Controlled release compositions
ZA9510687B (en) Sustained release caffeine formulation
EP1028709A4 (de) Neue "einmal täglich" sulfonylharnstoff- formulierung mit gesteuerter freisetzung
ZA9811461B (en) New formulation
AU7888298A (en) Sustained release cisapride minitablet formulation
HUP0201489A3 (en) New formulation
SG71789A1 (en) Controlled release compositions
EG24226A (en) Formulation
HRP20000213B1 (en) Extended release formulation
ZA985669B (en) New formulation
GB9902304D0 (en) Formulation
GB9724544D0 (en) Novel Formulation
ZA9810710B (en) Sustained release formulations comprising alpha-glucosidase-inhibitors
EP1008352A4 (de) Gehirnschützender wirkstoff
GB2322867B (en) Release agent
ZA9810773B (en) Revitalisation formulation
GB9706957D0 (en) Formulation
GB9927614D0 (en) Sterliant formulation
ZA9711374B (en) Sustained release cisapride mini-tablet formulation.
AP9901651A0 (en) Nitro-benzamide useful as anti-arrhytmic agent
GB9725275D0 (en) Formulation
GB9721807D0 (en) Formulation

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 19991230

Year of fee payment: 3

ODBI Application refused